Docetaxel and the bisphosphonates in the hormone-sensitive prostate cancer

Results: the results obtained gave us a substantial and reliable evidence that the addition of docetaxel in metastatic prostate cancer improves both overall and progression-free survival. These findings laid the foundation for the emergence of new standards in the treatment of this patient group. When non-metastatic prostate cancer, the addition of docetaxel improves progression-free survival, but so far there is no evidence to reliably assess the overall survival. The use of bisphosphonates in combination with standard treatments for metastatic prostate cancer leads to a small increase in survival, but the potential benefit of zoledronic acid and other bisphosphonates is low and is unlikely to make a big difference.